Maturitas
Volume 60, Issue 3 , Pages 216-222 , July 2008

Soy–tibolone combination—Effect on lipids in postmenopausal monkeys and women

  • Susan E. Appt

      Affiliations

    • Wake Forest University School of Medicine, Winston-Salem, NC, USA
    • Shared first authorship—equal contribution.
    • Corresponding Author InformationCorresponding author at: Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1040, USA Tel.: +1 336 716 1637; fax: +1 336 716 1515.
    • ,
  • Riina Törmälä

      Affiliations

    • Helsinki University Central Hospital, Department of Obstetrics and Gynecology, Helsinki, Finland
    • Shared first authorship—equal contribution.
    • ,
  • Adrian A. Franke

      Affiliations

    • Cancer Research Center of Hawaii, Honolulu, HI, USA
    • ,
  • Tomi S. Mikkola

      Affiliations

    • Helsinki University Central Hospital, Department of Obstetrics and Gynecology, Helsinki, Finland
    • ,
  • Matti J. Tikkanen

      Affiliations

    • Helsinki University Central Hospital, Department of Medicine, Helsinki, Finland
    • ,
  • Olavi Ylikorkala

      Affiliations

    • Helsinki University Central Hospital, Department of Obstetrics and Gynecology, Helsinki, Finland
    • ,
  • Thomas B. Clarkson

      Affiliations

    • Wake Forest University School of Medicine, Winston-Salem, NC, USA

Received 10 January 2008 ,Revised 18 June 2008 ,Accepted 26 June 2008.

References 

  1. Campisi R, Marengo FD. Cardiovascular effects of tibolone: a selective tissue estrogenic activity regulator. Cardiovasc Drug Rev. 2007;25:132–145
  2. Kloosterboer HJ. Tibolone: a steroid with a tissue-specific mode of action. J Steroid Biochem Mol Biol. 2001;76:231–238
  3. Verheu HAM, Timmer CJ, van Iersel MLPS, Delbressine LPC, Kloosterboer HJ. Pharmacokinetic parameters of tibolone and metabolites in plasma, urine, feces, and bile from ovariectomized cynomolgus monkeys after a single dose or multiple doses of tibolone. Drug Metab Distribution. 2007;35:1112–1118
  4. Christodoulakos GE, Lambrinoudaki IV, Economou EV, et al. Differential effect of hormone therapy and tibolone on lipids, lipoproteins, and the atherogenic index of plasma. J Cardiovasc Pharmacol. 2006;47:542–548
  5. Kalogeropoulos S, Petrogiannopoulos C, Gagos S, Kampas N, Kalogeropoulos G. The influence of 5-year therapy with tibolone on the lipid profile in postmenopausal women with mild hypercholesterolemia. Gynecol Endocrinol. 2004;18:227–232
  6. Bjarnason NH, Bjarnason K, Haarbo J, Bennick HJ, Christiansen C. Tibolone: influence on markers of cardiovascular disease. J Clin Endocrinol Metab. 1997;82:1752–1756
  7. Crona N, Silfverstolpe G, Samsoie G. A double-blind cross-over study on the effects of Org OD 14 compared to oestradiol valerate and placebo on lipid and carbohydrate metabolism in oophorectomized women. Acta Endocrinol. 1983;102:451–455
  8. Clarkson TB, Anthony MS, Wagner JD. A comparison of tibolone and conjugated equine estrogens effects on coronary artery atherosclerosis and bone density of postmenopausal monkeys. J Clin Endocrinol Metab. 2001;86:5396–5404
  9. Clarkson TB, Appt SE. Soy phytoestrogens (isoflavones) for estrogen replacement therapy—strengths and weaknesses. In:  Schneider HPG editors. Menopause – The State of the Art – in Research and Management: Proceedings of the 10th World Congress on the Menopause. Berlin, Germany, London, UK: Parthenon Publishing; 2003;p. 287–294
  10. Sacks FM, Lichtenstein A, Van Horn L, Harris W, Kris-Etherton P, Winston M. Soy protein, isoflavones and cardiovascular health: an American Heart Association Science Advisory for professionals from the Nutrition Committee. Circulation. 2006;113:1034–1044
  11. Franke AA, Custer LJ, Wilkens LR, et al. Liquid chromatographic-photodiode array mass spectrometric analysis of dietary phytoestrogens from human urine and blood. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;777:45–59
  12. Burstein M, Samaille J. On a rapid determination of the cholesterol bound to the serum alpha- and beta-lipoproteins. Clin Chim Acta. 1960;5:609
  13. Manual of laboratory operations: lipid research clinics program, vol. 1. Lipid and lipoprotein analysis. Bethesda, MD: National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health, Education, and Welfare Publication NIH; 1974, p. 75–268.
  14. Törmälä R, Appt SE, Clarkson TB, Tikkanen MJ, Ylikorkala O, Mikkola TS. Individual differences in equol production capability modulate blood pressure in tibolone treated postmenopausal women. Climacteric. 2007;10:471–479
  15. Wang GJ, Lapcik O, Hampl R, et al. Time-resolved fluoroimmunoassay of plasma daidzein and genistein. Steroids. 2000;65:339–348
  16. Nikander E, Kilkkinen A, Metsä-Heikkilä M, et al. A randomized placebo-controlled crossover trial with phytoestrogens in treatment of menopause in breast cancer patients. Obstet Gynecol. 2003;101:1213–1220
  17. Nikander E, Tiitinen A, Laitinen K, Tikkanen M, Ylikorkala O. Effects of isolated isoflavonoids on lipids, lipoproteins, insulin sensitivity, and ghrelin in postmenopausal women. J Clin Endocrinol Metab. 2004;89:3567–3572
  18. Clarkson TB, Anthony MS, Morgan TM. Inhibition of postmenopausal atherosclerosis progression—a comparison of the effects of conjugated equine estrogens and soy phytoestrogens. J Clin Endocrinol Metab. 2001;86:41–47
  19. Turley SD, Spady DK, Dietschy JM. Role of liver in the synthesis of cholesterol and the clearance of low density lipoproteins in the cynomolgus monkey. J Lipid Res. 1995;36:67–79
  20. Klein RL, Rudel LL. Cholesterol absorption and transport in thoracic duct lymph lipoproteins of nonhuman primates. Effect of dietary cholesterol level. J Lipid Res. 1983;24:343–356
  21. Manning PJ, Clarkson TB, Lofland HB. Cholesterol absorption, turnover, and excretion in hypercholesterolemic rhesus monkeys. Exp Mol Pathol. 1971;14:75–89
  22. McNamara DJ. Dietary cholesterol and atherosclerosis. Biochim Biophys Acta. 2000;1529:310–320
  23. Gu L, House SE, Prior RL, et al. Metabolic phenotype of isoflavones differ among female rats, pigs, monkeys, and women. J Nutr. 2006;136:1215–1221
  24. Lampe JW, Karr SC, Hutchins AM, Slavin JL. Urinary equol excretion with a soy challenge: influence of habitual diet. Proc Soc Exp Biol Med. 1998;217:335–339
  25. Setchell KD, Brown NM, Lydeking-Olsen E. The clinical importance of the metabolite equol—a clue to the effectiveness of soy and its isoflavones. J Nutr. 2002;132:3577–3584
  26. Appt SE, Clarkson TB, Register TC, Chen H. Dietary equol does not reproduce effects of dietary soy on cardiovascular disease risk variables; observations from postmenopausal monkeys (16th Annual Meeting, San Diego, September 28–October 1, 2005). Menopause. 2005;12:784
  27. Törmälä R, Appt SE, Clarkson TB, et al. Equol production capability is associated with favorable vascular function in postmenopausal women using tibolone; no effect of soy supplementation. Atherosclerosis. 2008;198:174–178
  28. Dewell A, Hollenbeck PL, Hollenbeck CB. Clinical review: a critical evaluation of the role of soy protein and isoflavone supplementation in the control of plasma cholesterol concentrations. J Clin Endocrinol Metab. 2006;91:772–780
  29. Bots ML, Evans GW, Riley W, et al. The effect of tibolone and continuous combined conjugated equine estrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: The Osteoporosis Prevention and Arterial Effects of Tibolone (OPAL) Study. Eur Heart J. 2006;27:746–755
  30. Clarkson TB. Does tibolone exacerbate atherosclerosis?. Eur Heart J. 2006;27:635–637[editorial]
  31. Nestel PJ, Yamashita T, Sasahara T, et al. Soy isoflavones improve systemic arterial compliance but not plasma lipids in menopausal and perimenopausal women. Arterioscler Thromb Vasc Biol. 1997;17:3392–3398
  32. van der Schouw YT, Pijpe A, Lebrun CE, et al. Higher usual dietary intake of phytoestrogens is associated with lower aortic stiffness in postmenopausal women. Arterioscler Thromb Vasc Biol. 2002;22:1316–1322
  33. Tikkanen MJ, Wahala K, Ojala S, Vihma V, Adlercreutz H. Effect of soybean phytoestrogen intake on low density lipoprotein oxidation resistance. Proc Natl Acad Sci. 1998;95:3106–3110
  34. Samman S, Lyons Wall PM, Chan GS, Smith SJ, Petocz P. The effect of supplementation with isoflavones on plasma lipids and oxidisability of low density lipoprotein in premenopausal women. Atherosclerosis. 1999;147:277–283
  35. Jenkins DJ, Kendall CW, Garsetti M, et al. Effect of soy protein foods on low-density lipoprotein oxidation and ex vivo sex hormone receptor activity-a controlled crossover trial. Metabolism. 2000;49:537–543
  36. Jenkins DJ, Kendall CW, Vidgen E, et al. Effect of soy-based breakfast cereal on blood lipids and oxidized low-density lipoprotein. Metabolism. 2000;49:1496–1500
  37. Wiseman H, O’Reilly JD, Adlercreutz H, et al. Isoflavone phytoestrogens consumed in soy decrease F(2)-isoprostane concentrations and increase resistance of low-density lipoprotein to oxidation in humans. Am J Clin Nutr. 2000;72:395–400

PII: S0378-5122(08)00195-3

doi: 10.1016/j.maturitas.2008.06.003

Maturitas
Volume 60, Issue 3 , Pages 216-222 , July 2008

Article Tools

* Image Usage & Resolution